专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

US20060025368A1 Growth hormone releasing hormone enhances vaccination response 审中-公开
标题翻译：生长激素释放激素增强疫苗接种反应
公开(公告)号：US20060025368A1
公开(公告)日：2006-02-02
申请号：US11186282
申请日：2005-07-21
申请人： Ruxandra Draghia-Akli , Patricia Brown , Amir Khan , William Davis
发明人： Ruxandra Draghia-Akli , Patricia Brown , Amir Khan , William Davis
IPC分类号： A61K48/00 , C12N15/87
CPC分类号： A61K39/39 , A61K2039/55516
摘要： This invention discloses compositions and methods of: vaccinating a subject; enhancing the vaccination efficiency; preparing a subject prior to vaccination response; and improving the clinical outcome after infectious challenge in a subject that has been vaccinated. More specifically, the invention pertains to delivering into a tissue of the subject a nucleic acid expression construct that encodes a growth-hormone-releasing-hormone (“GHRH”) before or concomitantly with delivering a vaccine to the subject, wherein, GHRH is expressed in vivo in the subject, wherein the subject comprises a human, pig, cow, bird, horse or any other animal species receiving a vaccine.
摘要翻译：本发明公开了一种组合物和方法：接种受试者; 提高疫苗接种效率; 在接种疫苗接种前准备受试者; 并且在接种疫苗的受试者中感染性挑战后改善临床结果。更具体地，本发明涉及在受试者的组织中递送编码生长激素释放激素（“GHRH”）的核酸表达构建体，或者同时向受试者递送疫苗，其中，GHRH被表达在受试者体内，其中受试者包括人，猪，牛，鸟，马或接受疫苗的任何其他动物物种。

32. 发明申请

US20050171046A1 Enhanced secretion / retention of growth hormone releasing hormone (GHRH) from muscle cells by species-specific signal peptide 有权
标题翻译：通过物种特异性信号肽增强肌肉细胞中生长激素释放激素（GHRH）的分泌/保留
公开(公告)号：US20050171046A1
公开(公告)日：2005-08-04
申请号：US11034682
申请日：2005-01-13
申请人： Ruxandra Draghia-Akli , Melissa Pope
发明人： Ruxandra Draghia-Akli , Melissa Pope
IPC分类号： C07K14/60 , C12N15/00 , A61K48/00 , C12N15/87
CPC分类号： C07K14/60 , C07K2319/02
摘要： One aspect of the current invention is a method designing and using species-specific or synthetic signal peptides and GHRH sequences for the purpose of preventing and/or treating chronic illness in a subject by utilizing methodology that administers a single dose of nucleic acid expression vector or nucleic acid expression construct encoding a GHRH or functional biological equivalent to a subject through a parenteral route of administration.
摘要翻译：本发明的一个方面是通过利用施用单剂量的核酸表达载体的方法来设计和使用物种特异性或合成的信号肽和GHRH序列，以便预防和/或治疗受试者的慢性疾病，核酸表达构建体通过胃肠外给药途径编码GHRH或与受试者的功能生物学等价物。

33. 发明申请

US20050004060A1 Plasmid mediated GHRH supplementation for renal failures 审中-公开
标题翻译：质粒介导的GHRH补充肾衰竭
公开(公告)号：US20050004060A1
公开(公告)日：2005-01-06
申请号：US10827918
申请日：2004-04-20
申请人： Ruxandra Draghia-Akli , Clara Scott , Patricia Brown
发明人： Ruxandra Draghia-Akli , Clara Scott , Patricia Brown
IPC分类号： A61K48/00
CPC分类号： A61K48/005
摘要： The present invention pertains to compositions and methods for plasmid-mediated supplementation. The compositions and methods are useful for treatment or prevention of kidney failure, treatment of anemia, and other conditions commonly associated with kidney failure in order to increase survival and improve welfare in subjects with chronic renal failure. Overall, the embodiments of the invention can be accomplished by delivering an isolated nucleic acid expression construct that encodes a GHRH or functional biological equivalent thereof into a tissue of a subject and allowing expression of the encoded gene in the animal. For example, when such a nucleic acid sequence is delivered into the specific cells of the subject, tissue specific constitutive expression is achieved. The embodiments of the invention also encompass delivery of a recombinant GHRH polypeptide or functional biological equivalent thereof. The preferred method for delivering the constitutive or inducible nucleic acid encoding sequences of GHRH or the functional biological equivalents thereof is directly into the cells of the subject by the process of in vivo electroporation.
摘要翻译：本发明涉及用于质粒介导的补充的组合物和方法。组合物和方法可用于治疗或预防肾衰竭，治疗贫血以及通常与肾功能衰竭相关的其它病症，以增加患有慢性肾功能衰竭的受试者的存活并改善福利。总的来说，本发明的实施方案可以通过将编码GHRH或其功能生物等同物的分离的核酸表达构建体递送到受试者的组织中并允许编码的基因在动物中表达来实现。例如，当将这样的核酸序列递送到受试者的特定细胞时，实现组织特异性组成型表达。本发明的实施方案还包括递送重组GHRH多肽或其功能生物学等同物。递送GHRH的组成型或诱导型核酸编码序列或其功能生物学等同物的优选方法通过体内电穿孔的方法直接进入受试者的细胞。

34. 发明授权

US08481504B2 Insulin-like growth factor (IGF-I) plasmid-mediated supplementation for therapeutic applications 有权
标题翻译：胰岛素样生长因子（IGF-I）质粒介导的治疗应用补充
公开(公告)号：US08481504B2
公开(公告)日：2013-07-09
申请号：US10798896
申请日：2004-03-11
申请人： Eric D. Rabinovsky , Ruxandra Draghia-Akli
发明人： Eric D. Rabinovsky , Ruxandra Draghia-Akli
IPC分类号： A61K48/00 , A01N63/00
CPC分类号： A61K48/005 , A61K38/00 , A61K48/0058 , C07K14/65 , C12N15/85 , C12N2830/008 , C12N2830/15 , C12N2830/85 , C12N2840/20
摘要： Composition and method for stimulating angiogenesis, stimulating myogenesis, upregulating angiogenic factors and angiopoietins, and treating the muscular and vascular complications of diabetes. Overall, the embodiments of the invention can be accomplished by delivering a heterologous nucleic acid sequence encoding insulin-like growth factor I (“IGF-I”) or a functional biological equivalent thereof into the cells of the subject and allowing expression of the encoded gene to occur while the modified cells are within the subject. The nucleic acid sequence maybe delivered by a vector system including a synthetic myogenic promoter and a 3′ untranslated region. The preferred method to deliver the constitutive or inducible nucleic acid encoding sequences of IGF-I or the functional biological equivalents thereof is directly into the cells of the subject by the process of in vivo electroporation.
摘要翻译：用于刺激血管发生，刺激肌肉发生，上调血管生成因子和血管生成素的组合物和方法，以及治疗糖尿病的肌肉和血管并发症。总的来说，本发明的实施方案可以通过将编码胰岛素样生长因子I（“IGF-I”）或其功能生物学等同物的异源核酸序列递送到受试者的细胞中并允许编码基因的表达来实现在修饰的细胞在受试者内时发生。核酸序列可以通过包含合成的肌原性启动子和3'非翻译区的载体系统递送。递送IGF-1的组成型或诱导型核酸编码序列或其功能生物学等同物的优选方法通过体内电穿孔的方法直接进入受试者的细胞。

35. 发明授权

US08133723B2 Vaccines against multiple subtypes of influenza virus 有权
标题翻译：针对流感病毒多种亚型的疫苗
公开(公告)号：US08133723B2
公开(公告)日：2012-03-13
申请号：US13158150
申请日：2011-06-10
申请人： Ruxandra Draghia-Akli , David B Weiner , Jian Yan , Dominick J Laddy
发明人： Ruxandra Draghia-Akli , David B Weiner , Jian Yan , Dominick J Laddy
IPC分类号： C12N15/00 , C12P21/06 , A61K39/145 , C07H21/02
CPC分类号： A61K39/145 , A61K9/0019 , A61K38/208 , A61K38/2086 , A61K39/12 , A61K47/34 , A61K2039/53 , A61K2039/54 , A61K2039/58 , A61K2039/70 , C07K14/005 , C12N7/00 , C12N2760/16034 , C12N2760/16122 , C12N2760/16134 , A61K2300/00
摘要： An aspect of the present invention is directed towards DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of influenza virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient. The DNA plasmid is capable of expressing a consensus influenza antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal, wherein the consensus influenza antigen comprises consensus hemagglutinin (HA), neuraminidase (NA), matrix protein, nucleoprotein, M2 ectodomain-nucleo-protein (M2e-NP), or a combination thereof. Preferably the consensus influenza antigen comprises HA, NA, M2e-NP, or a combination thereof. The DNA plasmid comprises a promoter operably linked to a coding sequence that encodes the consensus influenza antigen. Additionally, an aspect of the present invention includes methods of eliciting an immune response against a plurality of influenza virus subtypes in a mammal using the DNA plasmid vaccines provided.
摘要翻译：本发明的一个方面涉及能够在哺乳动物中产生针对多种流感病毒亚型的免疫应答的DNA质粒疫苗，其包含DNA质粒和药学上可接受的赋形剂。 DNA质粒能够以有效引发哺乳动物免疫应答的量在哺乳动物细胞中表达共有流感抗原，其中共有流感抗原包含共有血凝素（HA），神经氨酸酶（NA），基质蛋白，核蛋白，M2胞外结构域 - 核蛋白（M2e-NP）或其组合。优选地，共有流感抗原包含HA，NA，M2e-NP或其组合。 DNA质粒包含与编码共有流感抗原的编码序列可操作地连接的启动子。此外，本发明的一个方面包括使用提供的DNA质粒疫苗在哺乳动物中引发针对多种流感病毒亚型的免疫应答的方法。

36. 发明申请

US20120034256A1 HCV VACCINES AND METHODS FOR USING THE SAME 有权
标题翻译： HCV疫苗及其使用方法
公开(公告)号：US20120034256A1
公开(公告)日：2012-02-09
申请号：US13127008
申请日：2008-10-29
申请人： David B. Weiner , Krystle A. Lang , Jian Yan , Ruxandra Draghia-Akli , Amir Khan
发明人： David B. Weiner , Krystle A. Lang , Jian Yan , Ruxandra Draghia-Akli , Amir Khan
IPC分类号： A61K39/29 , A61P37/04 , C07K14/08 , A61P31/14 , C07H21/04 , C12N15/63
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K39/29 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , A61K2039/55 , C12N7/00 , C12N9/506 , C12N15/86 , C12N2710/24143 , C12N2770/24222 , C12N2770/24234
摘要： Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1 a/1 b NS3 and NS4A. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.
摘要翻译：公开了改进的抗HCV免疫原和编码它们的核酸分子。所公开的免疫原包括那些具有一致的HCV基因型1a / 1b NS3和NS4A的那些。公开了药物组合物，包含减毒活疫苗和减毒活疫苗的重组疫苗，并公开了针对HCV个体诱导免疫应答的方法。

37. 发明授权

US08058253B2 Growth hormone releasing hormone treatment to decrease cholesterol levels 有权
标题翻译：生长激素释放激素治疗降低胆固醇水平
公开(公告)号：US08058253B2
公开(公告)日：2011-11-15
申请号：US12307733
申请日：2007-07-05
申请人： Ruxandra Draghia-Akli , Amir S. Khan , Marta L. Fiorroto
发明人： Ruxandra Draghia-Akli , Amir S. Khan , Marta L. Fiorroto
IPC分类号： A61K48/00 , C12P21/06 , C12N15/09 , C12N15/00 , C12N5/00
CPC分类号： A61K48/005 , A61K38/25 , A61K48/0041 , A61K48/0083 , C12N2830/008
摘要： This invention is related to compositions and methods for decreasing cholesterol levels in a subject. The method utilizes a nucleic acid expression construct that encodes a growth-hormone-releasing-hormone (“GHRH”) that is delivered into a tissue of the subject, wherein, GHRH is expressed in vivo in the subject.
摘要翻译：本发明涉及降低受试者胆固醇水平的组合物和方法。该方法利用编码生物激素释放激素（“GHRH”）的核酸表达构建体，其被递送到受试者的组织中，其中GHRH在受试者体内表达。

38. 发明申请

US20090004716A1 COMPOSITIONS COMPRISING HIGH CONCENTRATION OF BIOLOGICALLY ACTIVE MOLECULES AND PROCESSES FOR PREPARING THE SAME 审中-公开
标题翻译：包含生物活性分子的高浓度的组合物及其制备方法
公开(公告)号：US20090004716A1
公开(公告)日：2009-01-01
申请号：US12126611
申请日：2008-05-23
申请人： Ruxandra Draghia-Akli , Henry Hebel , Ying Cai
发明人： Ruxandra Draghia-Akli , Henry Hebel , Ying Cai
IPC分类号： C12P1/00 , C12N15/00
CPC分类号： C12N1/06 , C12N15/1017
摘要： Large scale processes for producing high purity samples of biologically active molecules of interest from bacterial cells are disclosed. The methods comprise the steps of producing a lysate solution by contacting a cell suspension of said plurality of cells with lysis solution; neutralizing said lysate solution with a neutralizing solution to produce a dispersion that comprises neutralized lysate solution and debris; filtering the dispersion through at least one filter; performing ion exchange separation on said neutralized lysate solution to produce an ion exchange eluate; and performing hydrophobic interaction separation on said ion exchange eluate to produce a hydrophobic interaction solution. Further, provided are compositions comprising large scale amounts of plasmid DNA produced by the disclosed large scale processes.
摘要翻译：公开了从细菌细胞产生感兴趣的生物活性分子的高纯度样品的大规模方法。所述方法包括通过使所述多个细胞的细胞悬浮液与裂解液接触来产生裂解物溶液的步骤; 用中和溶液中和所述裂解物溶液以产生包含中和的裂解液和碎屑的分散体; 通过至少一个过滤器过滤色散; 在所述中和的裂解物溶液上进行离子交换分离以产生离子交换洗脱液; 并在所述离子交换洗脱液上进行疏水相互作用分离以产生疏水相互作用溶液。此外，提供了包含通过所公开的大规模方法生产的大量量的质粒DNA的组合物。

39. 发明申请

US20080269153A1 INCREASED STABILITY OF A DNA FORMULATION BY INCLUDING POLY-L-GLUTAMATE 审中-公开
标题翻译：通过包含聚-L-谷氨酸的DNA配方的增加的稳定性
公开(公告)号：US20080269153A1
公开(公告)日：2008-10-30
申请号：US11941921
申请日：2007-11-16
申请人： Ruxandra Draghia-Akli , Melissa Pope
发明人： Ruxandra Draghia-Akli , Melissa Pope
IPC分类号： A61K31/711
CPC分类号： A61K48/0008 , A61K39/00 , A61K2039/53 , C12N15/87
摘要： Aspects of the present invention is related to DNA vaccine formulations having enhanced stability comprising at least one DNA plasmid capable of expressing an antigen in cells of mammal and poly-L-glutamate; wherein the DNA plasmid is present in the vaccine formulation at a concentration of at least 1 mg/ml, and the poly-L-glutamate is present in the amount of weight that is 1% of the amount of DNA plasmid. Some aspects of the present invention is related to methods of stabilizing DNA plasmid in a DNA vaccine formulation. Additionally, the present invention is related to methods for introducing a DNA vaccine formulation having enhanced stability into a cell of a selected tissue in a recipient.
摘要翻译：本发明的方面涉及具有增强的稳定性的DNA疫苗制剂，其包含能够在哺乳动物和聚-L-谷氨酸的细胞中表达抗原的至少一种DNA质粒; 其中所述DNA质粒以至少1mg / ml的浓度存在于所述疫苗制剂中，并且所述多聚-L-谷氨酸盐以所述DNA质粒量的1％的量存在。本发明的一些方面涉及在DNA疫苗制剂中稳定DNA质粒的方法。此外，本发明涉及将具有增强的稳定性的DNA疫苗制剂引入受体中选定组织的细胞的方法。

40. 发明申请

US20050052630A1 Constant current electroporation device and methods of use 有权
标题翻译：恒流电穿孔装置及其使用方法
公开(公告)号：US20050052630A1
公开(公告)日：2005-03-10
申请号：US10657725
申请日：2003-09-08
申请人： Louis Smith , Ruxandra Draghia-Akli , Amir Khan , Robert Carpenter , Jeff Darnell
发明人： Louis Smith , Ruxandra Draghia-Akli , Amir Khan , Robert Carpenter , Jeff Darnell
IPC分类号： A61N1/30 , A61N1/32 , G03B27/42
CPC分类号： A61N1/0412 , A61N1/0476 , A61N1/327
摘要： An electroporation device which may be used to effectively facilitate the introduction of a macromolecule into cells of a selected tissue in a body or plant. The electroporation device comprises an electro-kinetic device (“EKD”) whose operation is specified by software or firmware. The EKD produces a series of programmable constant-current pulse patterns between electrodes in an array based on user control and input of the pulse parameters and allows the storage and acquisition of current waveform data. The electroporation device also comprises a replaceable electrode disk having an array of needle electrodes, a central injection channel for an injection needle, and a removable guide disk.
摘要翻译：可用于有效促进将大分子引入身体或植物中选定组织的细胞中的电穿孔装置。电穿孔装置包括其动作由软件或固件指定的电动装置（“EKD”）。 EKD基于用户控制和输入脉冲参数，在阵列中的电极之间产生一系列可编程恒定电流脉冲模式，并允许存储和采集电流波形数据。电穿孔装置还包括具有针电极阵列的可替换电极盘，用于注射针的中心注射通道和可移除引导盘。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式